Medscape: Analysis boosts Fluvoxamine for COVID, but what's the evidence?
UC expert says research may be useful, but more trials are needed
A report published recently in JAMA Open Network finds there's a strong likelihood that the antidepressant fluvoxamine (Luvox) may moderately lower rates of hospitalization due to COVID-19 in unvaccinated patients. However, outside experts cited by Medscape differ over whether the evidence from just three studies is strong enough to warrant adding the drug to the COVID-19 treatment arsenal. One of those experts sources is Carl Fichtenbaum, MD, of the Division of Infectious Diseases at the UC College of Medicine.
Carl Fichtenbaum, MD, of the Division of Infectious Diseases at the UC College of Medicine/Photo/Joe Fuqua II/UC Creative + Brand
"This research might be valuable, but the jury remains out until several other adequately powered and designed trials are completed," said Fichtenbaum, who's familiar with the findings. "I'm not sure how useful this is given we have several antiviral agents available. Why would we choose this over Paxlovid, remdesivir, or molnupiravir?"
According to Fichtenbaum, researchers began focusing on fluvoxamine after case reports about patients improving while on the medication. This led to further interest, he said, boosted by the drug's known ability to dampen the immune system.
Lead photo/Science News
Next Lives Here
The University of Cincinnati is classified as a Research 1 institution by the Carnegie Commission and is ranked in the National Science Foundation's Top-35 public research universities. UC's medical, graduate and undergraduate students and faculty investigate problems and innovate solutions with real-world impact. Next Lives Here.
Related Stories
Ohio looks to fast-track wastewater discharge permits
December 16, 2025
Bradford Mank, James B. Helmer Jr. Professor of Law at the University of Cincinnati, spoke with WVXU for a story about a proposal by the Ohio Environmental Protection Agency to streamline the way wastewater discharge permits are issued to data centers.
Tariff troubles for online shoppers
December 16, 2025
This year’s new regulations on tariffs and customs are leaving holiday shoppers with unexpected fees on some of their purchases, according to recent reporting by WLWT. Associate Dean of Impact and Partnerships for the University of Cincinnati’s Lindner College of Business Charles Sox spoke to WLWT about why shoppers are only just now feeling the impact, despite these policies being in effect for months.
Tips to avoid headaches this holiday season
December 15, 2025
A University of Cincinnati migraine expert offered a list of potential headache triggers around the holidays, and how you can try to avoid them, to 91.7 WVXU News. "There are a number of different factors that make this a very headache provocative time," said Vincent Martin, MD, professor of clinical medicine at the University of Cincinnati's College of Medicine and director of the Headache and Facial Pain Center at the Gardner Neuroscience Institute.